Pancreatic Cancer Research

ResearcherKanazawa UniversityActive in the last 2 years

Dai Inoue

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8429-9817; OpenAlex author ID A5005013150. Sources: OpenAlex.

Their work

Papers
15 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
60
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 4 papers

Papers 15

  1. Characteristics of ill-demarcated small pancreatic ductal adenocarcinoma on MRI: a multi-institutional retrospective cohort study. Co-author DOI 10.1007/s11604-026-02003-8↗
  2. Malignant potential of intraductal papillary mucinous neoplasm (IPMN) of the pancreas: imaging assessment of IPMN-derived cancer and concomitant pancreatic duc… First author DOI 10.1007/s11604-026-02067-6↗
  3. Optimizing Delayed-Phase CT Strategies for Early Pancreatic Ductal Adenocarcinoma Detection. First author DOI 10.1016/j.acra.2026.05.007↗
  4. Exceptional Long-Term Survival after Resection of Metachronous Liver and Lung Metastases Following Surgery for Pancreatic Cancer: A Case Report. Co-author DOI 10.70352/scrj.cr.26-0115↗
  5. Long-Term Survival after Curative Resection for Postoperative Dissemination of Pancreatic Ductal Adenocarcinoma: A Case Report. Co-author DOI 10.70352/scrj.cr.24-0022↗
  6. Safety of biliary drainage with 6-mm metallic stent for preoperative obstructive jaundice in pancreatic cancer: PURPLE SIX STUDY. Co-author DOI 10.1111/jgh.16524↗
  7. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  8. Efficacy of 6-mm diameter fully covered self-expandable metallic stents in preoperative biliary drainage for pancreatic ductal adenocarcinoma. First author DOI 10.1002/deo2.55↗
  9. CT-diagnosed extra-pancreatic extension of pancreatic ductal adenocarcinoma is a more reliable prognostic factor for survival than pathology-diagnosed extensio… First author DOI 10.1007/s00330-021-08180-6↗
  10. A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s10147-021-02001-y↗
  11. CT Abnormalities of the Pancreas Associated With the Subsequent Diagnosis of Clinical Stage I Pancreatic Ductal Adenocarcinoma More Than 1 Year Later: A Case-C… Co-author DOI 10.2214/ajr.21.26014↗
  12. Qualitative and quantitative evaluation for morphological changes of the splenic artery in autoimmune pancreatitis: novel imaging findings for differentiation … First author DOI 10.1007/s00261-018-1634-9↗
  13. Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a sin… Co-author DOI 10.1093/jjco/hyu159↗
  14. Lack of associations between genetic polymorphisms in GSTM1, GSTT1 and GSTP1 and pancreatic cancer risk: a multi-institutional case-control study in Japan. Co-author DOI 10.7314/apjcp.2014.15.1.391↗
  15. [FOLFIRINOX-induced hyperammonemic encephalopathy in a patient with pancreatic cancer]. Co-author PMID 25373377↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fumihito Toshima · 5 shared papers, 2018–2026 · strength 0.95
  2. Taku Higashihara · 2 shared papers, 2025–2026 · strength 0.50
  3. Makoto Takahashi · 2 shared papers, 2025–2026 · strength 0.50
  4. Satoshi Kobayashi · 2 shared papers, 2018–2026 · strength 0.39
  5. Toshifumi Gabata · 3 shared papers, 2018–2022 · strength 0.38
  6. Takuji Okusaka · 2 shared papers, 2021–2024 · strength 0.27
  7. S Kitamura · 1 shared paper, 2026 · strength 0.26
  8. Satoshi Kobayashi · 1 shared paper, 2026 · strength 0.26
  9. Keitaro Sofue · 1 shared paper, 2026 · strength 0.26
  10. Yoshihiko Fukukura · 1 shared paper, 2026 · strength 0.26
  11. Yoshiki Asayama · 1 shared paper, 2026 · strength 0.26
  12. Nobuhiro Fujita · 1 shared paper, 2026 · strength 0.26
  13. Yoshifumi Noda · 1 shared paper, 2026 · strength 0.26
  14. Shogo Takeuchi · 1 shared paper, 2026 · strength 0.26
  15. Satoshi Goshima · 1 shared paper, 2026 · strength 0.26
  16. Masato Matsuyama · 4 shared papers, 2014–2021 · strength 0.26
  17. Yasuhiro Morita · 1 shared paper, 2025 · strength 0.26
  18. Takeshi Azuma · 1 shared paper, 2025 · strength 0.26
  19. Yoshitaka Shimamaki · 1 shared paper, 2025 · strength 0.26
  20. Masayuki Ohtsuka · 1 shared paper, 2025 · strength 0.26
  21. Taiki Tsuji · 1 shared paper, 2026 · strength 0.24
  22. Takumi Miwa · 1 shared paper, 2026 · strength 0.24
  23. Yasuhiro Morita · 1 shared paper, 2026 · strength 0.24
  24. Shin Namiki · 2 shared papers, 2021–2022 · strength 0.24
  25. Yusuke Ishida · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.